FDAnews
www.fdanews.com/articles/102418-avastin-approved-for-new-indication-in-europe

Avastin Approved for New Indication in Europe

December 19, 2007

Roche’s Avastin was approved in Europe for the first-line treatment of patients with advanced renal cell cancer in combination with interferon.

The Avastin (bevacizumab) approval was based on data from the Phase III AVOREN trial in which patients who received Avastin in combination with interferon lived roughly twice as long without their disease progressing than those who received interferon alone, according to Roche.

Avastin is approved to treat several types of cancer in the U.S., Japan and the European Union.